# CONFERENCE READINESS REPORT: TCGA-PRAD (V3 CLINICAL VALIDITY)

**Target Conference:** 9th Theranostics World Congress (Osaka 2027)  
**Abstract Deadline:** November 1, 2026, 23:59 CET  
**Evaluation Date:** October 31, 2026  
**Final Decision:** **DEFINITIVE NO-GO FOR OSAKA SUBMISSION**  
**Repositioned Venues:** American Urological Association (AUA 2027) / American Medical Informatics Association (AMIA 2027)  

---

## 1. Compliance Audit
| Criteria | Requirement | Status | Audit Findings |
| :--- | :--- | :--- | :--- |
| **Theranostic Domain** | Must evaluate radioligand therapy or PSMA-PET | **FAIL** | TCGA-PRAD is surgical radical prostatectomy + bulk RNA-seq. Zero nuclear medicine data. Submitting to Osaka would violate scientific integrity. |
| **Data Authenticity** | Real public data | **PASS** | Verified GDC clinical XML supplements and STAR RNA counts across 314 patients (336 XML encounters). |
| **Endpoint Adjudication** | Differentiate prostate recurrence from second primaries | **PASS** | Separated 2 non-prostatic second primary cancers (TCGA-CH-5791, TCGA-HC-7080); primary definitive cohort has 70 prostate recurrence events and 191 double-negatives (n=261). |
| **Predictor Chronology** | Zero immortal time / surveillance leakage in baseline models | **PASS** | Established Day 0 (initial pathologic diagnosis) time origin. Postoperative surveillance PSA (median 511 days post-diagnosis) strictly excluded from baseline Cox models. |
| **Paired Molecular Benchmark** | Matched complete cases | **PASS** | Evaluated on identical n=187 patients (44 events, 143 non-events). Pure clinical AUROC = 0.710, Clin+RNA AUROC = 0.703; paired ΔAUROC = -0.008 (95% CI: [-0.073, +0.056], p=0.809). |
| **Survival Analysis** | Continuous RFS from initial diagnosis | **PASS** | Strict sensitivity cohort (n=255, 64 dated events): apparent C-index = 0.686, 5-fold CV C-index = 0.649. Schoenfeld test detected no statistically significant violation (p > 0.05). |
| **Reproducibility & Testing** | Automated test suite | **PASS** | 17/17 automated unit, pipeline, clinical validity, and scientific consistency tests pass in 0.6s. Playwright UI tests pass across Desktop, Tablet, and Mobile with 0 console errors. |

## 2. Conclusion
The study has been finalized to the highest clinical-validity research standard. Postoperative PSA leakage has been eradicated, survival time origins are explicitly indexed to initial pathologic biopsy diagnosis, and second non-prostatic malignancies have been cleanly separated. The work is ready for submission to leading oncology and medical informatics venues (AUA / AMIA 2027), while intentionally withheld from Osaka 2027 to uphold theranostic domain integrity.
